Sanofi posts positive results for drug in chronic sinusitis

PARIS (Reuters) - Sanofi and its U.S. partner Regeneron on Tuesday unveiled positive mid-stage trial results for their experimental drug dupilumab in patients with chronic sinusitis with nasal polyps. In a Phase IIa trial, the injectable drug met all primary and secondary endpoints in affected patients who did not respond to intranasal corticosteroids, Sanofi said in a statement. Dupilumab is also being tested by the drugmakers against two other allergic conditions - atopic dermatitis and asthma. (Reporting by Natalie Huet; Editing by Blaise Robinson)



via Health News Headlines - Yahoo News http://ift.tt/ZmBHk0